Beryl Drugs

{
  "main_header": {
    "sid": 302214,
    "name": "Beryl Drugs",
    "stock_name": "Beryl Drugs",
    "full_name": "Beryl Drugs Ltd",
    "name_url": "stocks-analysis/beryl-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.99",
    "chg": 0.99,
    "chgp": "4.95%",
    "dir": 1,
    "prev_price": "20.00",
    "mcapval": "10.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524606,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE415H01017",
    "curr_date": "Mar 19",
    "curr_time": "",
    "bse_nse_vol": "8.77 k",
    "exc_status": "Active",
    "traded_date": "Mar 19, 2026",
    "traded_date_str": "2026 03 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/beryl-drugs-302214-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Beryl Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3879194",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BerylDrugsLtd_mojoScore_3879194.png",
        "date": "2026-03-09 08:04:19",
        "description": "Beryl Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 March 2026. This shift reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals, despite an attractive valuation. The company’s stock price has also suffered, declining 7.10% on the day of the downgrade, underscoring investor concerns."
      },
      {
        "title": "Beryl Drugs Ltd Stock Falls to 52-Week Low of Rs.15.92",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beryl-drugs-ltd-stock-falls-to-52-week-low-of-rs1592-3869179",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BerylDrugsLtd_priceRelatedfactors_3869179.png",
        "date": "2026-03-04 10:40:43",
        "description": "Beryl Drugs Ltd’s share price declined to a fresh 52-week low of Rs.15.92 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent challenges faced by the company within the Pharmaceuticals & Biotechnology sector, as it continues to underperform both its sector peers and broader market indices."
      },
      {
        "title": "Beryl Drugs Ltd Stock Falls to 52-Week Low of Rs.16.2 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beryl-drugs-ltd-stock-falls-to-52-week-low-of-rs162-amidst-continued-downtrend-3865459",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BerylDrugsLtd_priceRelatedfactors_3865459.png",
        "date": "2026-03-02 14:15:14",
        "description": "Beryl Drugs Ltd’s shares declined sharply to a fresh 52-week low of Rs.16.2 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics."
      },
      {
        "title": "Why is Beryl Drugs Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-ltd-fallingrising-3861791",
        "imagepath": "",
        "date": "2026-02-28 01:08:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Volatility</strong></p>\n<p>The stock’s decline on 27-Feb was marked by heightened volatility, with an intraday price range of ₹2.14 and a low point of ₹19.61, representing a near 9.84% drop from previous levels. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure throughout the session. Such erratic trading behaviour, including a missed trading day in the last 20 sessions, underscores the stock’s current instability.</p>\n<p><strong>Underperformance Against Benchmarks</strong></p>\n<p>Beryl Drugs has consistently lagged behind the broader market indices and its sector over multiple time horizons. Over the past week, the stock declined by 7.66%, significantly underperforming the Sensex’s modest..."
      },
      {
        "title": "Are Beryl Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-beryl-drugs-ltd-latest-results-good-or-bad-3831472",
        "imagepath": "",
        "date": "2026-02-10 19:24:50",
        "description": "Beryl Drugs Ltd's latest financial results for Q3 FY26 indicate a challenging operational environment. The company reported a net loss of ₹0.17 crores, a significant decline compared to a profit of ₹0.05 crores in the same quarter last year. This marks a notable shift in profitability, reflecting ongoing operational difficulties.\n\nRevenue for the quarter decreased by 28.81% year-on-year to ₹3.78 crores, which is a substantial contraction from the previous year's figures. This decline suggests persistent demand challenges or potential losses in market share within its core segments of intravenous fluids and injectable products. The operating margin also turned negative at -5.29%, a stark contrast to the 11.11% margin reported in Q3 FY25, indicating that the company is struggling to cover its fixed costs effectively.\n\nThe financial performance over the nine-month period from April to December FY26 shows a sim..."
      },
      {
        "title": "Beryl Drugs Q3 FY26: Losses Mount as Revenue Erosion Accelerates",
        "link": "https://www.marketsmojo.com/news/result-analysis/beryl-drugs-q3-fy26-losses-mount-as-revenue-erosion-accelerates-3829160",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BerylDrugs_quaterlyResult_3829160.png",
        "date": "2026-02-09 20:31:25",
        "description": "Beryl Drugs Ltd. reported a troubling Q3 FY26 performance, posting a net loss of ₹0.17 crores against a profit of ₹0.05 crores in the same quarter last year, marking a complete reversal in profitability. The micro-cap pharmaceutical manufacturer saw revenues decline 28.81% year-on-year to ₹3.78 crores, whilst operating margins turned sharply negative at -5.29%, down from 11.11% in Q3 FY25. The stock, trading at ₹22.00 with a market capitalisation of ₹11.00 crores, has underperformed dramatically, falling 33.66% over the past year against the Sensex's 7.97% gain."
      },
      {
        "title": "Are Beryl Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-beryl-drugs-ltd-latest-results-good-or-bad-3829036",
        "imagepath": "",
        "date": "2026-02-09 19:15:05",
        "description": "Beryl Drugs Ltd's latest financial results for the quarter ended September 2025 reveal a complex operational landscape. The company reported net sales of ₹5.12 crores, reflecting a sequential growth of 6.89% from ₹4.79 crores in the previous quarter. However, this figure is notably 8.73% lower than the ₹5.61 crores recorded in the same quarter of the previous year, indicating challenges in sustaining revenue growth year-over-year.\n\nOperating margins showed improvement, rising to 14.26% from 11.27% in the preceding quarter, suggesting some success in cost management. However, the profit after tax (PAT) margin remained very low at just 0.20%, highlighting ongoing difficulties in converting revenue growth into substantial profitability. The net profit for the quarter was ₹0.01 crores, which represents no change from the previous year, but it is a significant decline of 50% compared to the previous quarter.\n\nTh..."
      },
      {
        "title": "Beryl Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-is-rated-sell-3771466",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BerylDrugsLtd_mojoScore_3771466.png",
        "date": "2025-12-26 21:51:48",
        "description": "Beryl Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance."
      }
    ],
    "total": 277,
    "sid": "302214",
    "stock_news_url": "https://www.marketsmojo.com/news/beryl-drugs-302214"
  },
  "announcements": [
    {
      "caption": "SUBMISSION OF DISCLOSURE UNDER REGULATION 7(2)",
      "datetime": "17-Mar-2026",
      "details": "SUBMISSION OF DISCLOSURE UNDER REGULATION 7(2)",
      "source": "BSE"
    },
    {
      "caption": "SUBMISSION OF DISCLOSURE UNDER REGULATION 29(2)",
      "datetime": "17-Mar-2026",
      "details": "SUBMISSION OF DISCLOSURE UNDER REGULATION 29(2)",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
      "datetime": "16-Mar-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sudhir Sethi",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Beryl Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-03-09 08:04:19

Beryl Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 March 2026. This shift reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals, despite an attractive valuation. The company’s stock price has also suffered, declining 7.10% on the day of the downgrade, underscoring investor concerns.

Read full news article

Beryl Drugs Ltd Stock Falls to 52-Week Low of Rs.15.92

2026-03-04 10:40:43

Beryl Drugs Ltd’s share price declined to a fresh 52-week low of Rs.15.92 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent challenges faced by the company within the Pharmaceuticals & Biotechnology sector, as it continues to underperform both its sector peers and broader market indices.

Read full news article

Beryl Drugs Ltd Stock Falls to 52-Week Low of Rs.16.2 Amidst Continued Downtrend

2026-03-02 14:15:14

Beryl Drugs Ltd’s shares declined sharply to a fresh 52-week low of Rs.16.2 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Read full news article

Why is Beryl Drugs Ltd falling/rising?

2026-02-28 01:08:58

Recent Price Movement and Volatility

The stock’s decline on 27-Feb was marked by heightened volatility, with an intraday price range of ₹2.14 and a low point of ₹19.61, representing a near 9.84% drop from previous levels. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure throughout the session. Such erratic trading behaviour, including a missed trading day in the last 20 sessions, underscores the stock’s current instability.

Underperformance Against Benchmarks

Beryl Drugs has consistently lagged behind the broader market indices and its sector over multiple time horizons. Over the past week, the stock declined by 7.66%, significantly underperforming the Sensex’s modest...

Read full news article

Are Beryl Drugs Ltd latest results good or bad?

2026-02-10 19:24:50

Beryl Drugs Ltd's latest financial results for Q3 FY26 indicate a challenging operational environment. The company reported a net loss of ₹0.17 crores, a significant decline compared to a profit of ₹0.05 crores in the same quarter last year. This marks a notable shift in profitability, reflecting ongoing operational difficulties. Revenue for the quarter decreased by 28.81% year-on-year to ₹3.78 crores, which is a substantial contraction from the previous year's figures. This decline suggests persistent demand challenges or potential losses in market share within its core segments of intravenous fluids and injectable products. The operating margin also turned negative at -5.29%, a stark contrast to the 11.11% margin reported in Q3 FY25, indicating that the company is struggling to cover its fixed costs effectively. The financial performance over the nine-month period from April to December FY26 shows a sim...

Read full news article

Beryl Drugs Q3 FY26: Losses Mount as Revenue Erosion Accelerates

2026-02-09 20:31:25

Beryl Drugs Ltd. reported a troubling Q3 FY26 performance, posting a net loss of ₹0.17 crores against a profit of ₹0.05 crores in the same quarter last year, marking a complete reversal in profitability. The micro-cap pharmaceutical manufacturer saw revenues decline 28.81% year-on-year to ₹3.78 crores, whilst operating margins turned sharply negative at -5.29%, down from 11.11% in Q3 FY25. The stock, trading at ₹22.00 with a market capitalisation of ₹11.00 crores, has underperformed dramatically, falling 33.66% over the past year against the Sensex's 7.97% gain.

Read full news article

Are Beryl Drugs Ltd latest results good or bad?

2026-02-09 19:15:05

Beryl Drugs Ltd's latest financial results for the quarter ended September 2025 reveal a complex operational landscape. The company reported net sales of ₹5.12 crores, reflecting a sequential growth of 6.89% from ₹4.79 crores in the previous quarter. However, this figure is notably 8.73% lower than the ₹5.61 crores recorded in the same quarter of the previous year, indicating challenges in sustaining revenue growth year-over-year. Operating margins showed improvement, rising to 14.26% from 11.27% in the preceding quarter, suggesting some success in cost management. However, the profit after tax (PAT) margin remained very low at just 0.20%, highlighting ongoing difficulties in converting revenue growth into substantial profitability. The net profit for the quarter was ₹0.01 crores, which represents no change from the previous year, but it is a significant decline of 50% compared to the previous quarter. Th...

Read full news article

Beryl Drugs Ltd is Rated Sell

2025-12-26 21:51:48

Beryl Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Read full news article

View All News